SCHEMBL20600768

SCHEMBL20600768

Nc1cnc(-c2ccc(F)cc2)c(Cl)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.49
ADORA1 P30542 6/20 0.49
ADORA2B P29275 2/20 0.38
ADORA3 P0DMS8 1/20 0.38
PIK3CD O00329 1/20 0.37
MAPK14 Q16539 3/20 0.37
MAPK11 Q15759 2/20 0.37
MAPK9 P45984 1/20 0.37
MAPK10 P53779 1/20 0.37
RAB9A P51151 2/20 0.37
ALDH1A1 P00352 1/20 0.37
ALOX5 P09917 1/20 0.37
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
KMT2A Q03164 1/20 0.36
KIT P10721 1/20 0.36
TDO2 P48775 1/20 0.36
MYC P01106 1/20 0.36
WDR5 P61964 1/20 0.36
DPP4 P27487 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29988053 0.86 ADORA2A (0.49) ADORA2AADORA1ADORA2BADORA3PIK3CD
SCHEMBL12077150 0.83 ADORA2A (0.64) ADORA2AADORA1ADORA2BADORA3MAPK14
SCHEMBL11370598 0.82 MEN1 (0.44) ADORA2AADORA1PIK3CDRAB9AALDH1A1
SCHEMBL20600732 0.81 ADORA2A (0.55) ADORA2AADORA1ADORA2BALDH1A1MEN1
SCHEMBL20600555 0.80 ADORA2A (0.46) ADORA2AADORA1ADORA2BALDH1A1MEN1
SCHEMBL3063909 0.80 ADORA2A (0.43) ADORA2AADORA1ADORA2BPIK3CDMAPK14
SCHEMBL11369579 0.79 ADORA2A (0.56) ADORA2AADORA1ADORA2BADORA3MAPK14
SCHEMBL17416946 0.78 PTPN11 (0.42) ADORA2AADORA1
SCHEMBL20658598 0.75 ADORA2A (0.49) ADORA2AADORA1ADORA2BMAPK14MAPK11
SCHEMBL29832087 0.75 ADORA2A (0.49) ADORA2AADORA1ADORA2BMAPK14MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4747255-A1 MODULATORS OF THE ADENOSINE A2A AND A2B RECEPTOR Ryvu Therapeutics S.A. (PL) 2026-05-27 EP disclosed
WO-2025018901-A1 MODULATORS OF THE ADENOSINE A2A AND A2B RECEPTOR Ryvu Therapeutics S.A. (PL) 2025-01-23 WO disclosed
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-11-26 US disclosed
WO-2020128036-A1 MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-06-25 WO disclosed
WO-2020128036-A1 MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-06-25 WO disclosed
EP-3645536-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR Ryvu Therapeutics S.A. (PL) 2020-05-06 EP disclosed
CN-110809577-A Modulators of adenosine A2A receptor 雷沃医疗有限公司 2020-02-18 CN disclosed
WO-2019002606-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR SELVITA S.A. (PL) 2019-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369665-A1 IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR ADORA2A, ADORA1, ADORA3 ADORA2A 1/4885ADORA1 2/4885ADORA2B 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.